Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx has received a $2M Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute to fund the development of a new strategy to detect pancreatic cancer.
One of the largest medical technology companies in the world will be the first tenant for the new I.D.E.A. Tempe campus. The Peripheral Intervention business of BD (Becton, Dickinson and Company) will be the first tenant in a new building at the Tempe Town Lake development. It will open in late 2019.
Mary O’Reilly, Ph.D., a philanthropy executive with extensive industry and laboratory experience, has been named the new Vice President, Bioscience Research Programs at the Flinn Foundation, where she will help implement grantmaking programs and other activities designed to advance Arizona’s bioscience sector.
GammaTile Therapy is the Next Step in the Expansion of Cesium to Additional Markets
Students from Arizona State University, University of Arizona and universities across the U.S. are spending eight weeks working side by side with some of the world’s most talented scientists, clinicians and researchers in an environment devoted to neuroscientific biomedical research and clinical care.
Researchers’ goal is to improve radiation testing through gene expression.
- Regulonix to use proceeds for advancing drug candidates toward human clinical trials
- Patented lead compounds demonstrated in animal models to be non-addictive and more effective than morphine
- Focusing on a validated biological pain target but with unique mechanism of action
The University of Arizona Mel and Enid Zuckerman College of Public Health provides free training and continuing education to the public health workforce in four states and the U.S. Affiliated Pacific Islands with a focus on the top public health issues of today: childhood obesity, the opioid epidemic and mental health care.
Lifelong cytomegalovirus infection may be beneficial, boosting the immune system in old age, when we need it most, according to a study led by University of Arizona researchers published in the Proceedings of the National Academy of Sciences.
TGen and Circuit Therapeutics lead discoveries that could help patients with neuro-related conditions such as Parkinson’s and drug addiction